NCT01939496View on ClinicalTrials.gov

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

PHASE4CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Diabetes Mellitus, Type 2Hypertension
Interventions
DRUG

Canagliflozin

One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.

DRUG

Placebo

One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.

Trial Locations (57)

Unknown

Birmingham

Gulf Shores

Avondale

Phoenix

Glendale

Los Angeles

Newport Beach

Pismo Beach

Rancho Cucamonga

Roseville

Sacramento

Spring Valley

Tustin

Denver

Brandon

Doral

Fort Lauderdale

Lake Worth

Lauderdale Lakes

Miami

Miami Lakes

Orlando

Pembroke Pines

Port Orange

West Palm Beach

Perry

Rincon

Indianapolis

Topeka

Lexington

Mandeville

Marrero

Metairie

Auburn

Elkridge

Dearborn

Kalamazoo

Jackson

St Louis

Morganville

Whiting

Albuquerque

Raleigh

Oklahoma City

Altoona

Jenkintown

Nashville

Austin

Dallas

Houston

Plano

Sugar Land

Salt Lake City

Renton

Carolina

Ponce Pr

Trujillo Alto

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT01939496 - Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents | Biotech Hunter | Biotech Hunter